News Report · Rare Disease

FDA Approves Kygevvi for Thymidine Kinase 2 Deficiency: 9.6 Years Mean Survival

June 11, 2026

Mean survival time with Kygevvi

9.6 years

Mean survival time without treatment

5.7 years

Mortality rate in treated patients

Mortality rate in untreated patients

36%

Clinical Perspective

Kygevvi is indicated for patients with thymidine kinase 2 deficiency who exhibit symptoms by age 12. The data supports a mean survival benefit of 9.6 years compared to untreated patients. What further research will clarify the long-term effects of Kygevvi on quality of life for these patients?

Editorial Team · Rare Disease

Kygevvi (doxecitine and doxribtimine) received FDA approval for the treatment of thymidine kinase 2 deficiency (TK2d), showing a mean survival time of 9.6 years compared to 5.7 years in untreated patients ^[1].

Clinical Context

Thymidine kinase 2 deficiency (TK2d) is a rare, inherited mitochondrial disorder that impairs the body's ability to produce and repair mitochondrial DNA (mtDNA). This condition can lead to significant muscle weakness and respiratory failure, severely impacting the quality of life for affected individuals. Current treatment options for TK2d are limited, and the disease is often underdiagnosed, with approximately 120 cases documented in the medical literature. The approval of Kygevvi addresses this unmet need by providing a new therapeutic option for patients who begin to show symptoms by the age of 12 ^[1].

Key Findings

The approval of Kygevvi was based on a comparison of survival rates between treated patients and an untreated external control group. In the analysis of 78 matched pairs, survival was significantly better in patients receiving Kygevvi, with only 4% mortality compared to 36% in the control group ^[1].
Mean survival time at 10 years was 9.6 years for the Kygevvi group versus 5.7 years for the control group ^[1].
The trials included 66 pediatric and 12 adult patients, all with genetically confirmed TK2d, treated with Kygevvi ^[2].
The primary endpoint was survival analysis, comparing treated patients to an untreated external control group from published literature ^[1].
The most common side effects reported were diarrhea, vomiting, increased liver enzymes, and abdominal pain ^[1].
Kygevvi is administered as an oral powder mixed with water, taken in three equal doses throughout the day with food ^[2].

Safety & Tolerability

Diarrhea reported with Kygevvi — exact frequency not available in public source summary ^[1].
Vomiting reported — exact frequency not available in public source summary ^[1].
Increased liver enzymes reported ^[1].
Abdominal pain reported ^[1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception ^[1].
Complete adverse event profile available in the full prescribing information for Kygevvi ^[1].

Study Design

The approval of Kygevvi was supported by data from one phase 2 clinical study, two retrospective chart review studies, and an expanded access program. The trials involved 78 patients with TK2d, all of whom had a symptom onset at or before 12 years of age. The primary endpoint was survival analysis, comparing treated patients with an untreated external control group. The studies were conducted across 39 centers in 20 countries, including the United States, and included both pediatric and adult patients ^[2].

FAQ

What is Kygevvi approved for?

Kygevvi (doxecitine and doxribtimine) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in patients who start to show symptoms by age 12 or younger. The FDA approved this drug on November 3, 2025, based on clinical trial data demonstrating improved survival outcomes.

How does Kygevvi work?

Kygevvi is a combination of two pyrimidine nucleosides, doxecitine and doxribtimine, which help improve the production and repair of mitochondrial DNA in patients with TK2d.

What is the recommended dose of Kygevvi?

Kygevvi is administered as an oral powder mixed with water, taken in three equal doses throughout the day with food. The exact dosing is based on the patient’s weight.

What are the most common side effects of Kygevvi?

The most common side effects reported with Kygevvi include diarrhea, vomiting, increased liver enzymes, and abdominal pain.

How does Kygevvi compare to untreated patients?

In clinical studies, patients treated with Kygevvi had a mean survival time of 9.6 years compared to 5.7 years for untreated patients, indicating a significant survival benefit.

Who qualifies for Kygevvi treatment?

Kygevvi is indicated for patients with thymidine kinase 2 deficiency who exhibit symptoms by age 12 or younger, as confirmed by genetic testing.

FDA Approves Kygevvi for Thymidine Kinase 2 Deficiency: 9.6 Years Mean Survival

FDA Approves Kygevvi for Thymidine Kinase 2 Deficiency: 9.6 Years Mean Survival

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly drug updates for Rare Disease in your inbox.

Related Drug Updates

FDA Approves Navepegritide for Achondroplasia: 1.5 cm Height Increase in Children

FDA Approves Tividenofusp Alfa for Hunter Syndrome: New Enzyme Replacement Therapy

FDA Reviews DTX401 Gene Therapy for GSDIa: GlucoGene Trial Results Expected in 2026

Verified HCP Portal